Non-VKA oral anticoagulants significantly reduced stroke or systemic embolism (OR 0.85; 95% CI 0.74-0.99) compared with warfarin in patients with atrial fibrillation and previous stroke or TIA.
Meta-Analysis (n=14,527)
Do non-vitamin-K-antagonist oral anticoagulants reduce stroke or systemic embolism in patients with atrial fibrillation and previous stroke or transient ischemic attack compared to warfarin?
Non-VKAs significantly reduce the risk of stroke, systemic embolism, and major bleeding compared to warfarin in patients with atrial fibrillation and a history of stroke or TIA.
Effect estimate: OR 0.85 (95% CI 0.74-0.99)
BACKGROUND AND PURPOSE: To assess whether the combined analysis of all phase III trials of nonvitamin-K-antagonist (non-VKA) oral anticoagulants in patients with atrial fibrillation and previous stroke or transient ischemic attack shows a significant difference in efficacy or safety compared with warfarin. METHODS: We searched PubMed until May 31, 2012, for randomized clinical trials using the following search items: atrial fibrillation, anticoagulation, warfarin, and previous stroke or transient ischemic attack. Studies had to be phase III trials in atrial fibrillation patients comparing warfarin with a non-VKA currently on the market or with the intention to be brought to the market in North America or Europe. Analysis was performed on intention-to-treat basis. A fixed-effects model was used as more appropriate than a random-effects model when combining a small number of studies. RESULTS: Among 47 potentially eligible articles, 3 were included in the meta-analysis. In 14 527 patients, non-VKAs were associated with a significant reduction of stroke/systemic embolism (odds ratios, 0.85 95% CI, 074-0.99; relative risk reduction, 14%; absolute risk reduction, 0.7%; number needed to treat, 134 over 1.8-2.0 years) compared with warfarin. Non-VKAs were also associated with a significant reduction of major bleeding compared with warfarin (odds ratios, 0.86 95% CI, 075-0.99; relative risk reduction, 13%; absolute risk reduction, 0.8%; number needed to treat, 125), mainly driven by the significant reduction of hemorrhagic stroke (odds ratios, 0.44 95% CI, 032-0.62; relative risk reduction, 57.9%; absolute risk reduction, 0.7%; number needed to treat, 139). CONCLUSIONS: In the context of the significant limitations of combining the results of disparate trials of different agents, non-VKAs seem to be associated with a significant reduction in rates of stroke or systemic embolism, hemorrhagic stroke, and major bleeding when compared with warfarin in patients with previous stroke or transient ischemic attack.
Ntaios et al. (Tue,) conducted a meta-analysis in Atrial fibrillation and previous stroke or transient ischemic attack (n=14,527). Nonvitamin-K-antagonist oral anticoagulants vs. Warfarin was evaluated on Stroke or systemic embolism (OR 0.85, 95% CI 0.74-0.99). Non-VKA oral anticoagulants significantly reduced stroke or systemic embolism (OR 0.85; 95% CI 0.74-0.99) compared with warfarin in patients with atrial fibrillation and previous stroke or TIA.